智通财经APP讯，微创脑科学(02172)发布截至2024年12月31日止年度的年度业绩，收入7.62亿元(人民币，下同)，同比增加14.44%;权益股东应占溢利2.54亿元，同比增加74.63%;每股基本盈利0.44元;拟派发末期股息每股0.11港元。
公告称，收益增加主要由于：海外业务实现突破性进展，报告期内收入较上年同期提升137.6%，贡献集团收入增量;脑动脉粥样硬化狭窄产品(包括Bridge®椎动脉雷帕霉素靶向洗脱支架系统、APOLLO™颅内动脉支架系统等)持续提升市场份额，实现收入显著增长;弹簧圈产品(包括NUMEN®可解脱栓塞弹簧圈等)得益于集采中标，加快空白市场开拓，对收入增长起到重要作用;近年来获批上市的多款急性缺血性脑卒中产品(包括Neurohawk®颅内取栓支架、X-track®远端导管等)加速医院准入和临床使用，贡献集团收入增量。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.